News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–36
Matches
76
Sources here
14
Companies here
1
Search results Stored financial headlines

Active search

76 matching headlines

Ticker or company: WSTMain company stories
Clear
Latest

Simply Wall Street Earnings

Is West Pharmaceutical Services (WST) Undervalued After Its Run to $349.42?

West Pharmaceutical Services (WST) has seen significant share price appreciation over the past year, currently trading at $349.42. While analysts project a fair value of around $404, suggesting it might be undervalued, the company's P/E ratio is higher than industry and peer averages. The potential for growth from GLP-1 related revenues and operational efficiencies are key factors in …

Main company 🇺🇸 United States
Read at Simply Wall Street
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
TradingView Earnings Main company 🇺🇸 United States

WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?

West Pharmaceutical Services (WST) stock has seen a significant rally, surging 38.1% since the end of March, driven by strong organic revenue growth and increased adjusted EPS. The company benefits from high demand for its proprietary products, particularly those used in biologics, biosimilars, and …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Analyst action Main company 🇺🇸 United States

West Pharmaceutical (WST) Upgraded to Buy: Here's Why

West Pharmaceutical (WST) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's underlying business and could lead to a favorable impact on its stock price. The …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

MarketBeat Earnings Main company 🇺🇸 United States

Zacks Research Has Optimistic Outlook of WST Q3 Earnings

Zacks Research has updated its Q3 2026 earnings per share (EPS) estimate for West Pharmaceutical Services (NYSE: WST) to $2.14, maintaining a "Hold" rating. This optimistic outlook follows West Pharmaceutical's recent strong quarterly performance, where the company exceeded earnings and revenue expectations and raised …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

West Pharmaceutical Services (NYSE:WST) Rating Lowered to Hold at Zacks Research

Zacks Research downgraded West Pharmaceutical Services (NYSE:WST) from "strong buy" to "hold" despite the company reporting strong quarterly results, exceeding EPS and revenue estimates. The broader analyst consensus remains a "Moderate Buy" with an average price target of $368.08. West Pharmaceutical Services posted Q2 …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketWatch Market update Main company 🇺🇸 United States

West Pharmaceutical Services Inc. stock underperforms Thursday when compared to competitors

West Pharmaceutical Services Inc. (WST) stock fell by 1.74% on Thursday, closing at $346.16, despite a generally positive trading day for the broader market, with the S&P 500 and Dow Jones Industrial Average both rising. The company's stock is now 10.32% below its 52-week …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

West Pharmaceutical Services, Inc. $WST Stock Position Reduced by Handelsbanken Fonder AB

Handelsbanken Fonder AB has reduced its stake in West Pharmaceutical Services (NYSE:WST) by 14.8% in the second quarter, selling 8,535 shares. Despite this, institutional investors collectively own 93.9% of the company, which recently reported strong quarterly earnings exceeding analyst estimates. West Pharmaceutical Services also …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

West (WST) Stock Looks Overvalued After A 47% One Year Run

West Pharmaceutical Services (WST) has seen a significant 46.9% stock price increase over the past year, leading to concerns about its current valuation. While the company's intrinsic value estimate is roughly in line with the market, several valuation checks suggest it may be overvalued, …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

West Pharmaceutical (WST) CFO converts RSUs, withholds shares for taxes

West Pharmaceutical Services Inc.'s CFO, Robert W. McMahon, recently converted 7,149.205 restricted stock units (RSUs) into common stock. A portion of these shares, totaling 3,109.19, were withheld at a price of $351.37 per share to cover tax liabilities or exercise costs. This transaction, which …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Assenagon Asset Management S.A. Has $23.25 Million Position in West Pharmaceutical Services, Inc. $WST

Assenagon Asset Management S.A. significantly reduced its stake in West Pharmaceutical Services (NYSE:WST) by 52.9% in Q2, retaining 64,754 shares valued at $23.25 million. Despite this, institutional investors own 93.9% of the company, and analysts maintain a consensus "Buy" rating with an average price …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

West Pharmaceutical Services, Inc. $WST Position Reduced by Seilern Investment Management Ltd

Seilern Investment Management Ltd reduced its stake in West Pharmaceutical Services (NYSE:WST) by 38.8% in Q2 2026, selling 87,791 shares and retaining 138,230 shares worth $49.6 million. Despite this reduction, WST remains Seilern's 7th largest holding, and institutional investors collectively own 93.9% of the …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Market update Main company 🇺🇸 United States

ETFs Investing in West Pharmaceutical Services, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of West Pharmaceutical Services, Inc. The ETFs are sorted by market value and include details such as weight, issuer, management style, expense ratio, assets under management (AUM), price, and 3-year NAV total return. …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

FMR LLC reports 5.0% ownership of West Pharmaceutical (WST) common stock

FMR LLC has disclosed a 5.0% beneficial ownership stake in West Pharmaceutical (WST) common stock, totaling 3,559,015.80 shares as of June 30, 2026. The filing indicates FMR LLC holds sole dispositive power over these shares and sole voting power over a slightly smaller portion. …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Bitget Earnings Main company 🇺🇸 United States

West Pharmaceutical Services declares Q3 2026 distribution of R$ 0.02 per unit

West Pharmaceutical Services has announced a Q3 2026 cash distribution of R$ 0.02 per unit (ISIN BRW2STBDR007). Shares will trade with entitlement through July 27, 2026, and the payment is scheduled for August 11, 2026. The announcement notes that this news brief was generated …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇺🇸 United States

MCK Stock Up as Q1 Earnings Beat on Specialty Growth, Guidance Raised

McKesson Corporation MCK reported first-quarter fiscal 2027 adjusted earnings per share (EPS) of $9.93, up 20% year over year. The figure beat the Zacks Consensus Estimate of $9.44 by 5.2%, driven by strong operational growth in North American Pharmaceutical and Oncology & Multispecialty, along …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇺🇸 United States

Broad-Based Growth Lifted West Pharmaceuticals (WST) in Q2

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sahm Earnings Main company 🇺🇸 United States

Stronger Q2 Results, Guidance Hike, Buybacks Might Change The Case For Investing In West (WST)

West Pharmaceutical Services (WST) reported strong Q2 results with increased sales and net income, alongside raising its full-year 2026 revenue outlook and completing significant share repurchases. The company's upgraded organic revenue guidance, driven by biologics and biosimilars, reinforces its growth-focused investment thesis. While potential …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The National Law Review Regulatory and legal Main company 🇺🇸 United States

Securities Fraud Class Action Filed Against West Pharmaceutical Services, Inc. (WST) - Levi & Korsinsky Reminds Investors of July 7, 2025

Levi & Korsinsky LLP has filed a securities fraud class action lawsuit against West Pharmaceutical Services, Inc. (WST), alleging that the company made false and misleading statements to investors between February 16, 2023, and February 12, 2025. The lawsuit claims West concealed significant destocking, …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Analyst action Main company 🇺🇸 United States

Citi Initiates West Pharmaceutical Services(WST.US) With Buy Rating, Announces Target Price $412

Citi has initiated coverage on West Pharmaceutical Services (WST.US) with a Buy rating. The firm has set a price target of $412 for the company's stock. This initiation suggests a positive outlook from Citi on West Pharmaceutical Services' future performance.

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketWatch Market update Main company 🇺🇸 United States

West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day

Shares of West Pharmaceutical Services Inc. (WST) increased by 2.05% to $347.94, outperforming its competitors on a strong trading day. The company's stock experienced its sixth consecutive day of gains, while the broader S&P 500 Index and Dow Jones Industrial Average also saw significant …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Capital return Main company 🇺🇸 United States

Is Stronger Q2 Results, Raised Outlook and Buybacks Altering The Investment Case For West Pharmaceutical Services (WST)?

In late July 2026, West Pharmaceutical Services reported second-quarter 2026 results showing higher sales and earnings than a year earlier, raised its full‑year 2026 revenue guidance, and completed US$454.28 million of share repurchases under its February 2026 buyback program. The company also issued third‑quarter …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Guidance Main company 🇺🇸 United States

West Pharmaceutical Services (WST) Raised Guidance, Is The Upside Already Priced In?

West Pharmaceutical Services (WST) reported stronger-than-expected Q2 results and raised its full-year guidance, driven by demand for biologics and biosimilars. Despite recent share price volatility, the stock is considered 15.6% undervalued with a fair value near $404, though its current P/E ratio is high …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall St Guidance Main company 🇺🇸 United States

West Pharmaceutical Services (WST) Raised Guidance, Is It Still 16% Undervalued?

West Pharmaceutical Services (WST) has seen renewed investor interest after reporting strong Q2 2026 results, raising its full-year revenue outlook, and continuing share buybacks and dividends. While a narrative suggests the stock is 16% undervalued with a fair value of $404, its current P/E …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Globe and Mail Earnings Main company 🇺🇸 United States

3 Reasons to Avoid WST and 1 Stock to Buy Instead

West Pharmaceutical Services (WST) stock has recently surged by 43%, but analysts recommend caution due to concerns about its long-term revenue growth, shrinking adjusted operating margin, and declining return on invested capital (ROIC). The article suggests that WST's current valuation of 36.4x forward P/E …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall St Earnings Main company 🇺🇸 United States

WST: High Value Injectable Demand And GLP 1 Exposure Will Drive Future Returns

Analysts have raised their target price for West Pharmaceutical Services (WST) to $404, driven by expectations of sustained demand for high-value injectable products and significant exposure to GLP-1 related therapies. While bullish sentiment focuses on strong earnings, product mix, and GLP-1 growth, some cautious …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall St Earnings Main company 🇺🇸 United States

West Pharmaceutical Services (WST) Is Down 6.0% After Raising 2026 Outlook and Expanding Daikyo Deal

West Pharmaceutical Services (WST) saw its stock fall 6.0% despite reporting stronger Q2 2026 results, raising its full-year 2026 revenue outlook, and expanding its partnership with Daikyo Seiko. The company's investment narrative focuses on the long-term need for high-spec drug packaging, but its rich …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Bitget Analyst action Main company 🇺🇸 United States

WEST PHARMACEUTICAL SERVICES INC : EVERCORE ISI RAISES TARGET PRICE TO $425 FROM $410

Evercore ISI has increased its target price for West Pharmaceutical Services Inc (WST.N) to $425 from $410. This adjustment by the financial services firm indicates a revised positive outlook on the company's stock performance. The news was reported by Reuters.

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
www.marketscreener.com Analyst action Main company 🇺🇸 United States

BNP Paribas Adjusts PT on West Pharmaceutical Services to $459 From $447, Maintains Outperform Rating

BNP Paribas has adjusted its price target for West Pharmaceutical Services to $459 from $447, while maintaining an Outperform rating. This adjustment comes amidst other analyst actions, with firms like Evercore ISI, Jefferies & Co, Rothschild & Co Redburn, and Deutsche Bank also modifying …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Weiss Asset Management LP Invests $1.99 Million in West Pharmaceutical Services, Inc. $WST

Weiss Asset Management LP recently acquired a new stake of 7,924 shares in West Pharmaceutical Services, valued at approximately $1.99 million. This investment comes as West Pharmaceutical Services reported strong quarterly earnings, surpassing analyst expectations for both EPS and revenue. The company also announced …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Renaissance Technologies LLC Has $52.55 Million Stock Position in West Pharmaceutical Services, Inc. $WST

Renaissance Technologies LLC significantly increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 100.2% in the first quarter, now holding 209,660 shares valued at $52.55 million. Other institutional investors like Norges Bank and Generation Investment Management also made substantial changes to their positions. …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Arrowstreet Capital Limited Partnership Purchases 210,112 Shares of West Pharmaceutical Services, Inc. $WST

Arrowstreet Capital Limited Partnership significantly increased its stake in West Pharmaceutical Services (NYSE:WST) during the first quarter of 2026, acquiring an additional 210,112 shares and bringing their total holdings to 510,516 shares valued at approximately $128 million. This comes as West Pharmaceutical Services reported …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

West Pharmaceutical Services, Inc. $WST Shares Acquired by Bank of Nova Scotia

Bank of Nova Scotia significantly increased its stake in West Pharmaceutical Services ($WST) by 337.8% in Q1, now owning 65,323 shares valued at $16.4 million. The company reported strong Q2 results, exceeding analyst expectations with an EPS of $2.37 and revenue of $872.3 million, …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇺🇸 United States

West Pharmaceutical (WST) Signs Decade Long Daikyo Distribution Deal Beyond Japan

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. West Pharmaceutical Services (NYSE:WST) has entered new long-term exclusive and non-exclusive distributorship agreements with Daikyo Seiko. West Pharmaceutical will distribute Daikyo products outside …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

West Pharmaceutical Services, Inc. Revenue Breakdown – MIL:1WST

West Pharmaceutical Services, Inc. (MIL:1WST) reported a total revenue of 2.62 billion EUR last year. The majority of this revenue, 2.12 billion EUR, came from its Proprietary Products segment, although this was a decrease from the previous year's 2.26 billion EUR. The United States …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

West Pharmaceutical Services, Inc. $WST Shares Sold by KBC Group NV

KBC Group NV reduced its stake in West Pharmaceutical Services (NYSE:WST) by 55.1% in the first quarter, selling over 11,000 shares. This comes as West Pharmaceutical Services reported a strong second quarter, exceeding revenue and EPS estimates, and raising its full-year guidance. Analysts maintain …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall Street Earnings Main company 🇺🇸 United States

West Pharmaceutical Services (WST) Stock Sees Margin Improvement Narrative Backed By Q2 2026 Results

West Pharmaceutical Services (WST) reported a strong Q2 2026 with increased revenue and basic EPS, demonstrating improved profitability with a trailing twelve-month net profit margin of 17%. The company's margin strength is attributed to higher-margin High Value Product components and GLP-1 related products, which …

WST main company
Sharemaestro market context Trend signal active 52 weeks +41.3% · Next-week setup positive 56.7% WST stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context